Innovent Biologics will present nearly ten sets of clinical data on its novel oncology molecules at the European Society of Medical Oncology Asia (ESMO Asia) Congress 2024 in Singapore from December 6-8. The presentations will cover a range of innovative therapies and combination regimens targeting various cancers.
IBI343 Shows Promise in Pancreatic Cancer
One of the highlights is an oral presentation of updated Phase 1 results for IBI343, a novel TOPO1i CLDN18.2 antibody-drug conjugate (ADC), in patients with previously-treated pancreatic cancer. The data from the dose expansion stage demonstrated encouraging efficacy and good safety, reinforcing confidence in its further development. According to Dr. Hui Zhou, Senior Vice President of Innovent, IBI343 is a pioneering CLDN18.2 ADC agent for pancreatic ductal adenocarcinoma (PDAC) treatment due to its unique design featuring an Fc-silent antibody, stable linker, and potent exatecan payload.
Combination Therapies with Sintilimab
Innovent will also present data on several combination therapies involving sintilimab, an anti-PD-1 antibody. These include:
- A Phase 2 study (BASKET II) evaluating mFOLFOX6 + bevacizumab + PD-1 monoclonal antibody in locally advanced microsatellite stable (MSS) colorectal cancer.
- A Phase 2 study of anlotinib plus sintilimab as first-line treatment for advanced colorectal cancer (APICAL-CRC).
- A Phase 2 study of hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and sintilimab as first-line treatment for unresectable intrahepatic cholangiocarcinoma (CHANCE 2203).
- A Phase 2 study of FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma (HCC).
- Updated results from a Phase 2 study of HAIC plus sintilimab and bevacizumab biosimilar in patients with advanced HCC.
- A Phase 2 study of anlotinib combined with sintilimab versus chemotherapy combined with immunotherapy in perioperative non-small cell lung cancer (NSCLC).
- A trial in progress (Phase 3) evaluating IBI310 (anti-CTLA-4 antibody) plus sintilimab as neoadjuvant treatment for resectable microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colon cancer.
- A trial in progress evaluating the efficacy and safety of combination therapy of sintilimab and chemotherapy with cryoablation in the first-line treatment of advanced non-squamous NSCLC.
Innovent's Commitment
Innovent aims to transform cancer treatment by delivering innovative, effective, and safe therapeutic options. With advanced technology platforms and a robust pipeline in immuno-oncology and antibody-drug conjugates, Innovent is dedicated to addressing unmet medical needs in cancer care.
